Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

Resistance to docetaxel is a major clinical problem in advanced prostate cancer (PCa). Although glucocorticoids (GCs) are frequently used in combination with docetaxel, it is unclear to what extent GCs and their receptor, the glucocorticoid receptor (GR), contribute to the chemotherapy resistance. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroon, Jan, Puhr, Martin, Buijs, Jeroen T, van der Horst, Geertje, Hemmer, Daniëlle M, Marijt, Koen A, Hwang, Ming S, Masood, Motasim, Grimm, Stefan, Storm, Gert, Metselaar, Josbert M, Meijer, Onno C, Culig, Zoran, van der Pluijm, Gabri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657186/
https://www.ncbi.nlm.nih.gov/pubmed/26483423
http://dx.doi.org/10.1530/ERC-15-0343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657186/
https://www.ncbi.nlm.nih.gov/pubmed/26483423
http://dx.doi.org/10.1530/ERC-15-0343

Ejemplares similares